Concepedia

Author

Valérie Cuvier

Inserm

Also Known As

V. Cuvier, Valerie Cuvier, Valérie Cuvier

13

Publications

528

Citations

8

H-Index

6

Concepts

All Affiliations

InsermCentre Hospitalier Régional et Universitaire de NancyUniversity of CambridgeUniversité de Rouen NormandieBrown University
VC

About

Valérie Cuvier is an author at Inserm specializing in sepsis, sepsis phenotyping, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

124

2

Sepsis Phenotyping

2

2

124

3

Emergency Medicine

1

1

64

4

Clinical Trials

1

1

60

5

Pharmacotherapy

1

1

60

Valérie Cuvier

×

7

Publications

506

Citations

7

H-Index

YearCitations

Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results

Dan Atar, Håkan Arheden, Alain Berdeaux,

European Heart Journal

2014

183

A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis

Timothée Lenglet, Lucette Lacomblez, Jean‐Louis Abitbol,

European Journal of Neurology

2014

127

Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial

Bruno François, Xavier Wittebole, Ricard Ferrer,

Intensive Care Medicine

2020

64

Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial

Bruno François, Simon Lambden, Tom Fivez,

The Lancet Respiratory Medicine

2023

60

A first‐in‐man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM‐1 receptor inhibition

Valérie Cuvier, Ulrike Lorch, Stephan Witte,

British Journal of Clinical Pharmacology

2018

40

Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial

Bruno François, Simon Lambden, Sébastien Gibot,

BMJ Open

2021

17

Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial

Bruno François, Simon Lambden, Jean–Jacques Garaud,

EClinicalMedicine

2023

15

Page 1